Manufacturer of Controlled Substances; Notice of Registration, 35243-35244 [2011-14960]
Download as PDF
<![CDATA[
35243
Federal Register / Vol. 76, No. 116 / Thursday, June 16, 2011 / Notices
Drug
Schedule
Oxymorphone (9652) ...................
II
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 15, 2011.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–14977 Filed 6–15–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 13, 2011,
American Radiolabeled Chemicals, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
following basic classes of controlled
substances:
srobinson on DSK4SPTVN1PROD with NOTICES
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Dimethyltryptamine (7435) ...........
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Dihydrocodeine (9120) .................
VerDate Mar<15>2010
17:18 Jun 15, 2011
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
Jkt 223001
Drug
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Heroin (9200) ...............................
Meperidine (9230) ........................
Metazocine (9240) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Phenazocine (9715) .....................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 15, 2011.
Drug
Hydrocodone (9193) .....................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
Schedule
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its customers
for Amphetamine (1100).
The company plans to acquire the
listed controlled substance in bulk from
a domestic source in order to
manufacture other controlled substances
in bulk for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 15, 2011.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–14968 Filed 6–15–11; 8:45 am]
[FR Doc. 2011–14974 Filed 6–15–11; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 1, 2011,
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
I
II
II
II
II
By Notice dated January 18, 2011, and
published in the Federal Register on
February 2, 2011, 76 FR 5829, Sigma
Aldrich Research Biochemicals, Inc., 1–
3 Strathmore Road, Natick,
Massachusetts 01760–2447, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
E:\FR\FM\16JNN1.SGM
16JNN1
Schedule
I
I
I
I
I
I
I
I
35244
Federal Register / Vol. 76, No. 116 / Thursday, June 16, 2011 / Notices
Drug
Schedule
srobinson on DSK4SPTVN1PROD with NOTICES
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Remifentanil (9739) ......................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
I
I
[FR Doc. 2011–14960 Filed 6–15–11; 8:45 am]
I
BILLING CODE 4410–09–M
I
DEPARTMENT OF LABOR
I
Office of the Secretary
Bureau of International Labor Affairs;
Office of Trade and Labor Affairs;
Bahrain—United States Free Trade
Agreement; Notice of Determination
Regarding Review of Submission
#2011–01
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Bureau of International Labor
Affairs, U.S. Department of Labor.
ACTION: Notice.
AGENCY:
17:18 Jun 15, 2011
Jkt 223001
The Office of Trade and Labor
Affairs (OTLA) gives notice that on June
10, 2011, Submission #2011–01 was
accepted for review pursuant to Article
15.4.2 of Chapter Fifteen (the Labor
Chapter) of the Bahrain—United States
Free Trade Agreement.
The submission was filed with OTLA
on April 21, 2011, by the American
Federation of Labor and Congress of
Industrial Organizations, with a
statement from the General Federation
of Bahrain Trade Unions. The
submission alleges the Government of
Bahrain has violated Article 15.1.1 of
the Labor Chapter of the Bahrain—
United States Free Trade Agreement by
failing to fulfill its obligations and
commitments under the International
Labour Organization Declaration on
Fundamental Principles and Rights at
Work and its Follow-up with regard to
the rights of association and nondiscrimination against trade unionists.
These allegations were supported by
specific factual descriptions which, if
substantiated, could demonstrate that
the Government of Bahrain’s actions
were inconsistent with its commitments
under the Labor Chapter.
The objectives of the review of the
submission will be to gather information
so that OTLA can better understand and
publicly report on the U.S.
Government’s views regarding whether
the Government of Bahrain’s actions
were consistent with the obligations set
forth in the Labor Chapter of the
Bahrain—United States Free Trade
Agreement.
DATES: Effective date: June 10, 2011.
FOR FURTHER INFORMATION CONTACT:
Gregory Schoepfle, Director, OTLA, U.S.
Department of Labor, 200 Constitution
Avenue, NW., Room S–5303,
SUMMARY:
The company plans to manufacture
reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Sigma Aldrich Research Biochemicals,
Inc. to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Sigma
Aldrich Research Biochemicals, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
VerDate Mar<15>2010
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Washington, DC 20210. Telephone:
(202) 693–4900 (this is not a toll-free
number).
SUPPLEMENTARY INFORMATION: Article
15.4.2 of the Labor Chapter of the
Bahrain—United States Free Trade
Agreement establishes that each Party’s
contact point shall provide for the
submission, receipt, and consideration
of communications from persons of a
Party on matters related to provisions of
the Labor Chapter and shall review such
communications in accordance with
domestic procedures. On December 14,
2006, the Department of Labor’s OTLA
was designated as the office to serve as
the contact point for administering the
labor provisions in free trade
agreements, including the Bahrain—
United States Free Trade Agreement. 71
FR 76691 (2006). The same Federal
Register notice informed the public of
the Procedural Guidelines that OTLA
would follow for the receipt and review
of public submissions. These Procedural
Guidelines are available at https://
www.dol.gov/ilab/programs/otla/
proceduralguidelines.htm. According to
the definitions contained in the
Procedural Guidelines (Section B) a
‘‘submission,’’ as used in the guidelines,
means ‘‘a communication from the
public containing specific allegations,
accompanied by relevant supporting
information, that another Party has
failed to meet its commitments or
obligations arising under a labor chapter
* * *.’’
The Procedural Guidelines specify
that OTLA shall consider six factors, to
the extent that they are relevant, in
determining whether to accept a
submission for review:
1. Whether the submission raises
issues relevant to any matter arising
under a labor chapter;
2. Whether a review would further the
objectives of a labor chapter;
3. Whether the submission clearly
identifies the person filing the
submission, is signed and dated, and is
sufficiently specific to determine the
nature of the request and permit an
appropriate review;
4. Whether the statements contained
in the submission, if substantiated,
would constitute a failure of the other
Party to comply with its obligations or
commitments under a labor chapter;
5. Whether the statements contained
in the submission or available
information demonstrate that
appropriate relief has been sought under
the domestic laws of the other Party, or
that the matter or a related matter is
pending before an international body;
and,
6. Whether the submission is
substantially similar to a recent
E:\FR\FM\16JNN1.SGM
16JNN1
]]>Agencies
[Federal Register Volume 76, Number 116 (Thursday, June 16, 2011)]
[Notices]
[Pages 35243-35244]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-14960]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated January 18, 2011, and published in the Federal
Register on February 2, 2011, 76 FR 5829, Sigma Aldrich Research
Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-
2447, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
Aminorex (1585)............................ I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
[[Page 35244]]
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Psilocybin (7437).......................... I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) I
(7470).
N-Benzylpiperazine (BZP) (7493)............ I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Ecgonine (9180)............................ II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Remifentanil (9739)........................ II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed
basic classes of controlled substances is consistent with the public
interest at this time. DEA has investigated Sigma Aldrich Research
Biochemicals, Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-14960 Filed 6-15-11; 8:45 am]
BILLING CODE 4410-09-M
